The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2022 | Differential dynamics of response between axi-cel and tisa-cel in R/R B-cell lymphoma
In this video, Nicholas Haradhvala, PhD, Broad Institute, Cambridge, MA, discusses a recent project in which single-cell RNA sequencing was used to analyze T-cells in patients with refractory B-cell lymphoma and compare responses to axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel). Dr Haradhvala first provides some background information on patient responses to chimeric antigen receptor T-cell (CAR-T) therapies, and then briefly discusses the method used in this study. Dr Haradhvala then explains the differences observed in the dynamics of axi-cel and tisa-cel, and how this influenced patient response to both products. Following this, Dr Haradhvala mentions that single-cell RNA sequencing also allowed investigators to analyze how CAR-T cells work across multiple treatments, and how further analyses with this method may influence future treatment decision-making in patients with B-cell lymphoma. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
